Table 1 Baseline characteristics of cancer patients according to their use of low-dose aspirin and non-aspirin NSAIDs from 3 months before diagnosis onward, a cohort study of 388,443 cancer patients diagnosed between Oct 2005 and Dec 2014 in Sweden
From: NSAID use and unnatural deaths after cancer diagnosis: a nationwide cohort study in Sweden
Low-dose aspirin | Non-aspirin NSAIDs | Patients without use of either medication (N = 192,333) | |||
|---|---|---|---|---|---|
Patients without use of low-dose aspirin (N = 273,123) | Patients with use of low-dose aspirin (N = 115,320) | Patients without use of non-aspirin NSAIDs (N = 275,449) | Patients with use of non-aspirin NSAIDs (N = 112,994) | ||
Male, N (%) | 134,055 (49.1) | 70,209 (60.9) | 145,684 (52.9) | 58,580 (51.8) | 95,413 (49.6) |
Mean age at diagnosis (SD), year | 65.27 (13.0) | 73.70 (10.2) | 69.18 (12.8) | 64.35 (12.2) | 66.70 (13.0) |
Calendar year of diagnosis, N (%) | |||||
2005–2008 | 80,797 (29.6) | 43,430 (37.6) | 71,183 (25.8) | 53,044 (46.9) | 45,283 (23.5) |
2009–2011 | 91,471 (33.5) | 40,789 (35.4) | 92,512 (33.6) | 39,748 (35.2) | 62,482 (32.5) |
2012–2014 | 100,855 (36.9) | 31,101 (27.0) | 111,754 (40.6) | 20,202 (17.9) | 84,568 (44.0) |
Highest educational level, N (%) | |||||
Beyond secondary school | 71,038 (26.0) | 19,899 (17.3) | 62,018 (22.5) | 28,919 (25.6) | 48,441 (25.2) |
Secondary school | 111,169 (40.7) | 41,880 (36.3) | 106,489 (38.7) | 46,560 (41.2) | 76,880 (40.0) |
Primary school | 88,207 (32.3) | 51,940 (45.0) | 103,726 (37.6) | 36,421 (32.2) | 64,993 (33.8) |
Missing | 2709 (1.0) | 1601 (1.4) | 3216 (1.2) | 1094 (1.0) | 2019 (1.0) |
Occupation, N (%) | |||||
Blue collar | 23,767 (8.7) | 3498 (3.0) | 16,918 (6.1) | 10,347 (9.2) | 14,852 (7.7) |
White collar | 52,211 (19.1) | 7721 (6.7) | 37,922 (13.8) | 22,010 (19.5) | 33,300 (17.3) |
Farmers | 2079 (0.8) | 625 (0.5) | 1873 (0.7) | 831 (0.7) | 1452 (0.8) |
Self-employed | 9401 (3.4) | 2420 (2.1) | 7674 (2.8) | 4147 (3.7) | 6117 (3.2) |
Retired or unemployed | 143,688 (52.6) | 86,694 (75.2) | 166,437 (60.4) | 63,945 (56.6) | 103,998 (54.1) |
Unclassified or missing | 41,946 (15.4) | 14,355 (12.5) | 44,597 (16.2) | 11,704 (10.4) | 32,614 (16.9) |
Cohabitation status, N (%) | |||||
Cohabitating | 136,088 (49.8) | 56,219 (48.8) | 129,433 (47.0) | 62,874 (55.6) | 91,427 (47.5) |
Non-cohabitating | 106,358 (38.9) | 46,411 (40.3) | 107,994 (39.2) | 44,775 (39.6) | 74,280 (38.6) |
Missing | 30,677 (11.2) | 12,690 (11.0) | 38,022 (13.8) | 5345 (4.7) | 26,626 (13.8) |
Cancer type, N (%) | |||||
Prostate cancer | 49,566 (18.1) | 26,095 (22.6) | 49,439 (18.0) | 26,222 (23.2) | 32,590 (16.9) |
Breast cancer | 43,544(15.9) | 10,755 (9.3) | 36,298 (13.2) | 18,001 (15.9) | 28,985 (15.1) |
Colorectal cancer | 30,024 (11.0) | 13,221 (11.5) | 31,576 (11.5) | 11,669 (10.3) | 21,764 (11.3) |
Non-melanoma skin cancer | 14,972 (5.5) | 10,289 (8.9) | 20,044 (7.3) | 5217 (4.6) | 11.894 (6.2) |
Hematopoietic malignancy | 18,518 (6.8) | 9425 (8.2) | 21,340 (7.7) | 6603 (5.8) | 14.155 (7.4) |
Lung cancer | 18,017 (6.6) | 8693 (7.5) | 19,965 (7.2) | 6745 (6.0) | 13,210 (6.9) |
Severe cancer (esophagus, liver and pancreas) | 12,267 (4.5) | 4494 (3.9) | 13,829 (5.0) | 2932 (2.6) | 10,055 (5.2) |
Others | 86,215 (31.6) | 32,348 (28.1) | 82,917 (30.1) | 35,646 (31.5) | 59,680 (31.0) |
Cancer stage at diagnosisa, N (%) | |||||
Localized limited | 79,238 (29.0) | 28,324 (24.5) | 75,534 (27.4) | 32,028 (28.3) | 55,302 (28.7) |
Localized advanced | 16,403 (6.0) | 7570 (6.6) | 16,778 (6.1) | 7195 (6.4) | 11,295 (5.9) |
Regional spread | 29,086 (10.7) | 10,704 (9.3) | 26,872 (9.8) | 12,918 (11.4) | 19,221 (10.0) |
Distant metastasis | 29,759 (10.9) | 10,668 (9.2) | 30,902 (11.2) | 9525 (8.4) | 22,431 (11.7) |
Unknown | 100,119 (36.7) | 48,629 (42.2) | 104,015 (37.8) | 44,733 (39.6) | 69,929 (36.4) |
Not applicable | 18,518 (6.8) | 9425 (8.2) | 21,348 (7.7) | 6595 (5.8) | 14,155 (7.3) |
History of psychiatric disorders, N (%) | |||||
No | 239,491 (87.7) | 99,110 (85.9) | 239,975 (87.1) | 97,777 (86.5) | 167,971 (87.3) |
Yes | 33,632 (12.3) | 16,210 (14.1) | 35,474 (12.9) | 15,217 (13.5) | 24,362 (12.7) |
Chronic Disease Score, N (%) | |||||
0 | 105,699 (38.7) | 9004 (7.8) | 75,296 (27.3) | 39,407 (34.9) | 70,037 (36.4) |
1–2 | 111,484 (40.8) | 28,884 (25.1) | 97,093 (35.3) | 43,275 (38.3) | 77,666 (40.4) |
3–5 | 49,854 (18.3) | 65,309 (56.6) | 88,137 (32.0) | 27,026 (23.9) | 39,307 (20.4) |
> 6 | 6086 (2.2) | 12,123 (10.5) | 14,923 (5.4) | 3286 (2.9) | 5323 (2.8) |